Alpha PSMA & New Targets in Prostate Cancer | ProsTIC/PCF Global Webinar

This is for hardcore PSMA aficionados!! This is the 7th of our ProsTIC/Prostate Cancer Foundation Global Webinars focussing on all things PSMA theranostics (you can find the rest in our back catalogue stretching back to April 2020). We peek into theranostics beyond what we currently have with beta-emitters like LuPSMA, into the tantalising world of alpha-PSMA theranostics. Multidisciplinary researchers from the PCF-funded TACTICAL project give a sneak into current and future work.

Hear from Memorial Sloan Kettering Cancer Center experts Prof Mike Morris, Dr Lisa Bodei and Dr Jason Lewis about very exciting developments in DLL3 imaging and theranostics in neuroendocrine prostate cancer; Dr Marwa Rahimi (Radiochemist at Peter MacCallum Cancer Centre) and David Pattison (Nuclear Medicine Physician, Royal Brisbane Hospital), overview Lead-212 targeted alpha therapy; and Dr Megan Crumbaker (Medical Oncologist (St Vincent's Hoapital, Sydney) who discusses Actinium-225 clinical data.

Plus Dr James Buteau (Nuclear Medicine Physician, Peter Mac) on the Q&A Co-hosted by Declan Murphy and Michael Hofman from the GU Cast studio in Melbourne. along with Dr Howard Soule and Dr Andrea Miyahira from the PCF in California.

Also available as a classical audio podcast in all the usual places, or directly here